Rovi and Ferrer build national Spanish vaccine plant
Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production capacity is planned to reach 10 million vaccines against seasonal flu and 30 million against pandemic flu. Alentia, which was only recently created, announced that the technology will be licensed in form Novartis.
During the construction of the production plant, Alentia Biotech will be entitled to market seasonal flu vaccines under a co-marketing regime with Novartis Vaccines & Diagnostics for an estimated five-year period. Once the production plant comes into operation, Alentia Biotech and Novartis Vaccines and Diagnostics will market the vaccines manufactured at the plant through a commercial joint venture.
The plant is the late fruit of a Protocol of Intent signed by ROVI on 30 June, 2009 with the Ministry of Health and Social Policy and the Andalusian Regional Government’s Departments of Innovation, Science and Enterprises and of Health. The public-private partnership envisaged a national production centre for seasonal and pandemic flu vaccines to supply the entire Spanish population.